Providers who order several tests are more likely to order low-value prostate cancer screening
TUESDAY, Jan. 10, 2023 (HealthDay News) — Low-value prostate cancer screening is common in primary care, according to a study published in the January issue of the Journal of the American Board of Family Medicine.
Chris Gillette, Ph.D., from the Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues used data from the National Ambulatory Medicare Care Survey (2013 to 2016 and 2018) to assess the proportion of U.S. primary care visits at which low-value prostate cancer screening is ordered, as well as characteristics associated with low-value prostate cancer screening.
The researchers found 6.71 low-value prostate-specific antigens (PSAs) per 100 visits and 1.65 low-value digital rectal exams (DREs) per 100 visits. The odds of ordering a low-value PSA increased by 49 percent and the odds of performing a low-value DRE increased by 37 percent for each additional service ordered by primary care providers.
“As health care systems move toward a more value-based care system — where the benefit of services provided outweighs any risks — providers need to engage patients in these discussions on the complexity of this testing,” Gillette said in a statement. “Ultimately, when and if to screen is a decision best left between a provider and the patient.”
Retinal Imaging Can ID Atrial Fibrillation Years Before Diagnosis 
U.S. Adults May Not Understand Their Risk for Vascular Disease 
Screening + Online Cognitive Behavioral Therapy Program Aids Nurses" Mental Health .jpeg)
Higher Intake of Saturated, Animal Fats May Increase Mortality in Prostate Cancer 
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer 
Focal Therapy Use Remains Uncommon in Nonmetastatic Prostate Cancer 
Risk for Prostate Cancer Elevated With Higher Ultraprocessed Food Intake 
Rates of Active Surveillance for Low-Risk Prostate Cancer High for Veterans 
.jpg)
